Used primarily in pharmaceutical research, this compound serves as a key intermediate in the synthesis of immunomodulatory drugs. It is notably involved in the development of agents that target protein degradation pathways, especially cereblon E3 ubiquitin ligase modulators. These agents are investigated for their potential in treating various cancers, including multiple myeloma and myelodysplastic syndromes. Its structure enables selective binding to biological targets, enhancing the degradation of disease-causing proteins. Additionally, it has been explored in the design of novel therapeutics for inflammatory and autoimmune conditions due to its ability to influence cytokine production and immune cell activity.